The UK and US have established a significant trade agreement that will keep zero tariffs on British medicine exports being sold in the US market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has pledged to increase expenditure on medicines through the National Health Service (NHS). This pledge secures that duties on these vital goods will stay at nothing for a timeframe of the next three years.
This deal is in response to previous threats to significantly raise import taxes on patented drug imports, with increases discussed reaching 100%.
"This agreement with the Britain reinforces the global environment for cutting-edge drugs and establishes much-needed fairness to American-British pharmaceutical trade," a statement said.
Trade Impact
Medicines are one of the the United Kingdom's biggest exports to the US, which is by far the largest market for major UK drugmakers.
Statistics indicate that in the year leading up to September, the UK exported drugs worth billions to the US. This figure accounted for nearly one-fifth of total UK exports in that timeframe.
"This deal protects employment, boosts funding and paves the way for the UK to become a global hub for medical research," the Business and Trade Secretary remarked.
Detailed British Pledges
The deal entails several notable changes from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it considers new therapies to be unaffordable by 25%.
- Boosted Medicine Funding: There is a target to increase overall health service expenditure on medicines from 0.3% of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The percentage drug companies must return to the NHS to stay within budget will be capped at 15%. Last year, repayments exceeded twenty percent.
Recent Tensions
This agreement takes place against a ongoing dispute between the drug companies and the UK government over spending levels and approval rates.
This friction were heightened by claims that American consumers were charged significantly more for the equivalent treatments than consumers in the Britain and the EU.
Recently, several significant drug company projects in the UK have been paused or cancelled, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
The Science Minister acknowledged that the NHS needed to increase expenditure on medicines, noting that its spending on drugs had declined as a percentage of its resources over the past decade.
